Acute meyloid leukemia
Conditions
Interventions
Intervention group:Azacitidine 50-75 mg/m2, d1-7
Lenalidomide 5-10 mg/m2, d10-30
6 weeks for one cylce, 8-12 cycles.
Sponsors
The Second Affiliated Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years old, male or female; 2. Diagnosisd with acute myeloid leukemia; 3. No complete remission was achieved after more than 2 courses of initial induction chemotherapy, or disease recurrence occurred in the past; 4. Received allogeneic hematopoietic stem cell transplantation and achieved hematopoietic reconstitution; 5. No history of grade II-IV acute graft-versus-host disease or moderate to severe chronic graft-versus-host disease after transplantation; 6. No active infection requiring intravenous anti infective therapy; 7. No organ dysfunction; 8. Voluntarily participated in the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Morphological relapse; 2. Impaired renal or liver function (defined as total bilirubin greater than or equal to 2.5 times the upper limit of normal (ULN), aspartate aminotransferase or alanine aminotransferase greater than or equal to 3.0 times the ULN, and the estimated glomerular filtration rate less than or equal to 40 ml/min); 3. Received anti-tumor treatment within 28 days before protocol treatment; 4. Allergic to study drug or other contraindications to azacytidine and/or lenalidomide; 5. Poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 years disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2 years overall survival;2 years cumulative recurrence rate;Cumulative incidence rate of acute and chronic graft-versus-host disease; | — |
Countries
China
Contacts
Public ContactKong Peiyan
The Second Affiliated Hospital, Army Medical University
Outcome results
None listed